Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACKR3 | P25106 | 3/20 | 0.46 |
| ▸ | CCR3 | P51677 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 4/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.40 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | TYK2 | P29597 | 1/20 | 0.39 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13003255 | 0.91 | ACKR3 (0.46) | ACKR3CCR3KDRDRD2DRD4 | |
| SCHEMBL12409942 | 0.84 | KDR (0.42) | ACKR3CCR3KDRDRD2DRD4 | |
| SCHEMBL12893522 | 0.81 | KDR (0.46) | KDRTBK1 | |
| SCHEMBL13003253 | 0.79 | GSK3B (0.45) | ACKR3TBK1 | |
| SCHEMBL14091145 | 0.77 | ACKR3 (0.49) | ACKR3 | |
| SCHEMBL13003995 | 0.77 | KDR (0.36) | ACKR3CCR3KDRCDK5DYRK1A | |
| SCHEMBL14091142 | 0.76 | ACKR3 (0.44) | ACKR3TBK1 | |
| SCHEMBL12409965 | 0.76 | KDR (0.36) | ACKR3CCR3KDRCDK5DYRK1A | |
| SCHEMBL13600348 | 0.75 | GPR183 (0.53) | KDRTBK1 | |
| SCHEMBL14091079 | 0.75 | TBK1 (0.40) | TBK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144591-A1 | BENZIMIDAZOLE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144591-A1 | BENZIMIDAZOLE DERIVATIVES AND METHODS OF USE THEREOF | GPR119, GK, GCK | ACKR3 2905/4885CCR3 1378/4885KDR 4071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.